Skip to main content

Table 2 Best symptom and functionality response while receiving GXR, by psychiatric comorbidities of interest (post-hoc analyses)

From: A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Comorbidity (MedDRA preferred term)

Improvement, n (%)a

ADHD symptom assessmentb

Functionality assessmentb

School performance

Homelife

Oppositional defiant disorder, n = 92

64 (69.6)

54 (58.7)

51 (55.4)

Learning disability, n = 70

52 (74.3)

51 (72.9)

48 (68.6)

Anxiety, n = 53

39 (73.6)

38 (71.7)

36 (67.9)

Autism spectrum disorder, n = 35

24 (68.6)

24 (68.6)

21 (60.0)

  1. ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release, MedDRA Medical Dictionary for Regulatory Activities
  2. aPercentages were calculated using the number of patients in the respective comorbidity categories as denominator
  3. bGeneral physician assessment